Selected research
Market Structure
Global Xerostomia (Dry Mouth) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Xerostomia (Dry Mouth) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Xerostomia (Dry Mouth) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Xerostomia (Dry Mouth) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Xerostomia (Dry Mouth) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Xerostomia (Dry Mouth) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Xerostomia (Dry Mouth) Therapeutics include Acacia Pharma, Church & Dwight, Inc., Colgate-Palmolive Company, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., OraCoat, Parnell Pharmaceuticals, Inc., Pendopharm and GlaxoSmithKline plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Xerostomia (Dry Mouth) Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Xerostomia (Dry Mouth) Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Xerostomia (Dry Mouth) Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Xerostomia (Dry Mouth) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
Xerostomia (Dry Mouth) Therapeutics Segment by Company
Acacia Pharma
Church & Dwight, Inc.
Colgate-Palmolive Company
Hikma Pharmaceuticals PLC
Lupin Pharmaceuticals, Inc.
OraCoat
Parnell Pharmaceuticals, Inc.
Pendopharm
GlaxoSmithKline plc
Pfizer, Inc.
Sun Pharmaceuticals Industries Ltd.
Xerostomia (Dry Mouth) Therapeutics Segment by Type
Salivary Stimulants
Salivary Substitutes
Dentifrices
Xerostomia (Dry Mouth) Therapeutics Segment by Application
OTC
Prescription
Xerostomia (Dry Mouth) Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Xerostomia (Dry Mouth) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Xerostomia (Dry Mouth) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Xerostomia (Dry Mouth) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Xerostomia (Dry Mouth) Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Xerostomia (Dry Mouth) Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Xerostomia (Dry Mouth) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Xerostomia (Dry Mouth) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Salivary Stimulants
- Salivary Substitutes
- Dentifrices
Applications
- OTC
- Prescription
Companies covered
- Acacia Pharma
- Church & Dwight, Inc.
- Colgate-Palmolive Company
- Hikma Pharmaceuticals PLC
- Lupin Pharmaceuticals, Inc.
- OraCoat
- Parnell Pharmaceuticals, Inc.
- Pendopharm
- GlaxoSmithKline plc
- Pfizer, Inc.
- Sun Pharmaceuticals Industries Ltd.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Xerostomia (Dry Mouth) Therapeutics Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Xerostomia (Dry Mouth) Therapeutics Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Xerostomia (Dry Mouth) Therapeutics Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Xerostomia (Dry Mouth) Therapeutics Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Xerostomia (Dry Mouth) Therapeutics Market Dynamics
- 2.1 Xerostomia (Dry Mouth) Therapeutics Industry Trends
- 2.2 Xerostomia (Dry Mouth) Therapeutics Industry Drivers
- 2.3 Xerostomia (Dry Mouth) Therapeutics Industry Opportunities and Challenges
- 2.4 Xerostomia (Dry Mouth) Therapeutics Industry Restraints
3 Xerostomia (Dry Mouth) Therapeutics Market by Manufacturers
- 3.1 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Manufacturers (2021-2026)
- 3.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Manufacturers (2021-2026)
- 3.3 Global Xerostomia (Dry Mouth) Therapeutics Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Xerostomia (Dry Mouth) Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Xerostomia (Dry Mouth) Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Xerostomia (Dry Mouth) Therapeutics Manufacturers, Product Type & Application
- 3.7 Global Xerostomia (Dry Mouth) Therapeutics Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Xerostomia (Dry Mouth) Therapeutics Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Xerostomia (Dry Mouth) Therapeutics Players Market Share by Revenue in 2025
- 3.8.3 2025 Xerostomia (Dry Mouth) Therapeutics Tier 1, Tier 2, and Tier 3
4 Xerostomia (Dry Mouth) Therapeutics Market by Type
- 4.1 Xerostomia (Dry Mouth) Therapeutics Type Introduction
- 4.1.1 Salivary Stimulants
- 4.1.2 Salivary Substitutes
- 4.1.3 Dentifrices
- 4.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Type
- 4.2.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Type (2021-2032)
- 4.2.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Market Share by Type (2021-2032)
- 4.3 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Type
- 4.3.1 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Type (2021-2032)
- 4.3.3 Global Xerostomia (Dry Mouth) Therapeutics Revenue Market Share by Type (2021-2032)
5 Xerostomia (Dry Mouth) Therapeutics Market by Application
- 5.1 Xerostomia (Dry Mouth) Therapeutics Application Introduction
- 5.1.1 OTC
- 5.1.2 Prescription
- 5.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Application
- 5.2.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Application (2021-2032)
- 5.2.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Market Share by Application (2021-2032)
- 5.3 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Application
- 5.3.1 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Application (2021-2032)
- 5.3.3 Global Xerostomia (Dry Mouth) Therapeutics Revenue Market Share by Application (2021-2032)
6 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region
- 6.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region (2021-2032)
- 6.2.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region (2021-2026)
- 6.2.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Xerostomia (Dry Mouth) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Xerostomia (Dry Mouth) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Xerostomia (Dry Mouth) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Xerostomia (Dry Mouth) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Region
- 7.1 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Region
- 7.1.1 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Region (2021-2026)
- 7.1.3 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Region (2027-2032)
- 7.1.4 Global Xerostomia (Dry Mouth) Therapeutics Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Xerostomia (Dry Mouth) Therapeutics Revenue (2021-2032)
- 7.2.2 North America Xerostomia (Dry Mouth) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Xerostomia (Dry Mouth) Therapeutics Revenue (2021-2032)
- 7.3.2 Europe Xerostomia (Dry Mouth) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue (2021-2032)
- 7.4.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Xerostomia (Dry Mouth) Therapeutics Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Xerostomia (Dry Mouth) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Acacia Pharma
- 8.1.1 Acacia Pharma Company Information
- 8.1.2 Acacia Pharma Business Overview
- 8.1.3 Acacia Pharma Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Acacia Pharma Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.1.5 Acacia Pharma Recent Developments
- 8.2 Church & Dwight, Inc.
- 8.2.1 Church & Dwight, Inc. Company Information
- 8.2.2 Church & Dwight, Inc. Business Overview
- 8.2.3 Church & Dwight, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Church & Dwight, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.2.5 Church & Dwight, Inc. Recent Developments
- 8.3 Colgate-Palmolive Company
- 8.3.1 Colgate-Palmolive Company Company Information
- 8.3.2 Colgate-Palmolive Company Business Overview
- 8.3.3 Colgate-Palmolive Company Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Colgate-Palmolive Company Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.3.5 Colgate-Palmolive Company Recent Developments
- 8.4 Hikma Pharmaceuticals PLC
- 8.4.1 Hikma Pharmaceuticals PLC Company Information
- 8.4.2 Hikma Pharmaceuticals PLC Business Overview
- 8.4.3 Hikma Pharmaceuticals PLC Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Hikma Pharmaceuticals PLC Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.4.5 Hikma Pharmaceuticals PLC Recent Developments
- 8.5 Lupin Pharmaceuticals, Inc.
- 8.5.1 Lupin Pharmaceuticals, Inc. Company Information
- 8.5.2 Lupin Pharmaceuticals, Inc. Business Overview
- 8.5.3 Lupin Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Lupin Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.5.5 Lupin Pharmaceuticals, Inc. Recent Developments
- 8.6 OraCoat
- 8.6.1 OraCoat Company Information
- 8.6.2 OraCoat Business Overview
- 8.6.3 OraCoat Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 OraCoat Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.6.5 OraCoat Recent Developments
- 8.7 Parnell Pharmaceuticals, Inc.
- 8.7.1 Parnell Pharmaceuticals, Inc. Company Information
- 8.7.2 Parnell Pharmaceuticals, Inc. Business Overview
- 8.7.3 Parnell Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Parnell Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.7.5 Parnell Pharmaceuticals, Inc. Recent Developments
- 8.8 Pendopharm
- 8.8.1 Pendopharm Company Information
- 8.8.2 Pendopharm Business Overview
- 8.8.3 Pendopharm Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Pendopharm Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.8.5 Pendopharm Recent Developments
- 8.9 GlaxoSmithKline plc
- 8.9.1 GlaxoSmithKline plc Company Information
- 8.9.2 GlaxoSmithKline plc Business Overview
- 8.9.3 GlaxoSmithKline plc Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 GlaxoSmithKline plc Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.9.5 GlaxoSmithKline plc Recent Developments
- 8.10 Pfizer, Inc.
- 8.10.1 Pfizer, Inc. Company Information
- 8.10.2 Pfizer, Inc. Business Overview
- 8.10.3 Pfizer, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Pfizer, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.10.5 Pfizer, Inc. Recent Developments
- 8.11 Sun Pharmaceuticals Industries Ltd.
- 8.11.1 Sun Pharmaceuticals Industries Ltd. Company Information
- 8.11.2 Sun Pharmaceuticals Industries Ltd. Business Overview
- 8.11.3 Sun Pharmaceuticals Industries Ltd. Xerostomia (Dry Mouth) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Sun Pharmaceuticals Industries Ltd. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 8.11.5 Sun Pharmaceuticals Industries Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Xerostomia (Dry Mouth) Therapeutics Value Chain Analysis
- 9.1.1 Xerostomia (Dry Mouth) Therapeutics Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Xerostomia (Dry Mouth) Therapeutics Production Mode & Process
- 9.2 Xerostomia (Dry Mouth) Therapeutics Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Xerostomia (Dry Mouth) Therapeutics Distributors
- 9.2.3 Xerostomia (Dry Mouth) Therapeutics Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst